Seres Therapeutics, Inc. (MCRB) Total Return Calculator with Dividends Reinvested

Seres Therapeutics, Inc.

Popular:

The total return for Seres Therapeutics, Inc. (MCRB) stock is -40.33% over the past 12 months. So far it's down 39.74% this year. The 5-year total return is -97.60%, meaning $10,000 invested in MCRB stock 5 years ago would be worth $240 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in MCRB 1 year ago, it would be worth $5,967 today — you'd have lost $4,033.

With Dividends Reinvested$5,967-40.33%

Price Only (No DRIP)$5,967-40.33%

Period2025-03-05 → 2026-03-04

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in MCRB

1Y$5,967-$4,033 (-40.3%)-40.3% CAGR

3Y$832-$9,168 (-91.7%)-56.4% CAGR

5Y$240-$9,760 (-97.6%)-52.6% CAGR

10Y$154-$9,846 (-98.5%)-34.1% CAGR

15Y$89-$9,911 (-99.1%)-27.0% CAGR

20Y$89-$9,911 (-99.1%)-21.0% CAGR

30Y$89-$9,911 (-99.1%)-14.6% CAGR

Seres Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading MCRB total return...

As of 2026-03-05

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-39.74%	—	-39.74%	—	$6,026
1Y	-40.33%	-40.33%	-40.33%	—	$5,967
3Y	-91.68%	-56.35%	-91.68%	—	$832
5Y	-97.60%	-52.59%	-97.60%	—	$240
10Y	-98.46%	-34.11%	-98.46%	—	$154
15Y	-99.11%	-27.02%	-99.11%	—	$89
20Y	-99.11%	-21.04%	-99.11%	—	$89
30Y	-99.11%	-14.57%	-99.11%	—	$89

Risk & Highlights

Best Year+631.34%2020

Worst Year-74.07%2023

Max Drawdown-71.57%2025-11-19 → 2026-02-17

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-42.31%	-42.31%	—	+0.41%	-42.7pp
2025	-11.80%	-11.80%	—	+16.64%	-28.4pp
2024	-40.64%	-40.64%	—	+24.00%	-64.6pp
2023	-74.07%	-74.07%	—	+24.81%	-98.9pp
2022	-36.65%	-36.65%	—	-19.95%	-16.7pp

MCRB underperformed the S&P 500 by 57.01pp over the past year (-40.33% vs +16.68%).

Loading summary...

MCRB Peers' Total Return

Biotechnology · Top 11 by market cap

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
MCRBSeres Therapeutics, Inc.	$80M	-31.9%	-39.7%	-40.3%	—	-91.7%	-97.6%	-98.5%
VRTXVertex Pharmaceuticals Incorporated	$121.4B	+4.2%	+5.7%	-2.8%	—	+63.9%	+125.4%	+425.4%
REGNRegeneron Pharmaceuticals, Inc.	$108.4B	+2.7%	+1.6%	+15.1%	+0.5pp	+1.5%	+71.6%	+94.0%
PHGEBiomX Inc.	$82.8B	+38.2%	+194.4%	-48.8%	—	-93.2%	-99.5%	-99.7%
ARGXargenx SE	$46.4B	-8.6%	-10.8%	+17.8%	—	+119.3%	+158.7%	+3159.0%
ALNYAlnylam Pharmaceuticals, Inc.	$43.3B	-1.2%	-18.2%	+31.3%	—	+63.9%	+128.3%	+444.7%
CAICaris Life Sciences, Inc.	$33.2B	-6.5%	-26.4%	-29.1%	—	-29.1%	-29.1%	-29.1%
RPRXRoyalty Pharma plc	$26.8B	+7.6%	+22.7%	+43.1%	+2.7pp	+42.2%	+21.0%	+16.7%
BNTXBioNTech SE	$26.0B	-1.6%	+7.4%	-9.6%	—	-21.1%	+10.1%	+643.8%
MRNAModerna, Inc.	$22.6B	+41.4%	+87.3%	+64.2%	—	-59.9%	-56.3%	+210.8%
ROIVRoivant Sciences Ltd.	$21.4B	+39.6%	+34.6%	+175.9%	—	+275.1%	+197.6%	+183.8%

Compare:MCRB vs VRTX MCRB vs REGN MCRB vs PHGE MCRB vs VRTX vs REGN

About MCRB Dividend Returns

Seres Therapeutics, Inc. (MCRB) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of MCRB over the past year?

Seres Therapeutics, Inc. (MCRB) delivered a return of -40.33% over the past year. Since MCRB does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in MCRB be worth today?

A $10,000 investment in Seres Therapeutics, Inc. one year ago would be worth $5,967 today, representing a loss of $4,033.

Q3Does MCRB pay dividends?

Seres Therapeutics, Inc. (MCRB) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For MCRB, the total return equals the price-only return.

Q4Did MCRB beat the S&P 500?

No, Seres Therapeutics, Inc. (MCRB) underperformed the S&P 500 by 57.01 percentage points over the past year. MCRB delivered a total return of -40.33%, compared to the S&P 500's 16.68%. This means a passive S&P 500 index fund outperformed MCRB by 57.01pp during this period.

Q5What is MCRB's worst drawdown?

Seres Therapeutics, Inc. (MCRB) experienced a maximum drawdown of -71.57% over the past year, declining from its peak on 2025-11-19 to its trough on 2026-02-17. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is MCRB's long-term total return over 10, 20, or 30 years?

Seres Therapeutics, Inc. (MCRB) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is -98.5% (-34.1% CAGR) — $10,000 would have grown to $154. Over 20 years: -99.1% total return (-21.0% CAGR) — $10,000 → $89. Over 30 years: -99.1% total return (-14.6% CAGR) — $10,000 → $89. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was MCRB's best and worst year?

Seres Therapeutics, Inc.'s best calendar year was 2020 with a total return of 631.3%. Its worst year was 2023 with a total return of -74.1%. This range shows the volatility investors should expect — the difference between the best and worst year is 705.4 percentage points.